Table 1.

Demographic, clinical, and laboratory features of 90 patients with JIA^*

Variable	Value
Age, years	13.8 (10.8, 16.5)
Age at JIA onset, years	3.7 (2.1, 8.2)
Female sex, no (%)	75 (83.3)
Male sex, no. (%)	15 (16.7)
Disease duration, years	8.5 (5.3, 12.6)
ILAR category, no. (%)
Persisted oligoarthritis	22 (24.4)
Extended oligoarthritis	33 (36.7)
Polyarthritis RF−	22 (24.4)
Polyarthritis RF+	3 (3.3)
Systemic	10 (11.1)
Patients in clinical remission off medications, no. (%)	15 (16.7)
Patients in clinical remission on medications, no. (%)	75 (83.3)
MTX†	21 (28)
Biologic agents (anti‐TNF or anti–IL‐6)†	40 (53.3)
MTX + a biologic agent†	14 (18.7)
Duration of clinical remission, months	10.7 (7.3, 16.6)
CHAQ, median (minimum – maximum) score	0 (0, 0.25)
No. of joints with active disease	0 (0, 0)
VAS, 0–10 scale	0 (0, 0)
Parent/patient's assessment of overall health, 0–10 scale	0 (0, 0)
CRP, mg/dl‡	0 (0, 0)
ESR, mm/hour§	9 (6, 11)

^*Values are the median (interquartile range [IQR]) unless indicated otherwise. Anti‐TNF = anti–tumor necrosis factor; CHAQ = Childhood Health Assessment Questionnaire; CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; ILAR = International League of Associations for Rheumatology; JIA = juvenile idiopathic arthritis; MTX = methotrexate; RF+ = positive rheumatoid factor; RF– = negative rheumatoid factor; VAS = visual analog scale.

^†Data were available for 75 patients.

^‡Normal range <0.46 md/dl.

^§Normal range <20 mm/hour.